Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15050557
Abstract: Checkpoint inhibitors (CPI) represent a novel therapeutical strategy with a high efficacy both in solid and hematological cancers. They act by reactivating the immune system against neoplastic cells but may, in turn, cause immune-related adverse… read more here.
Keywords: hematological autoimmune; autoimmune complications; checkpoint inhibitors; hematological extra ... See more keywords